efinopegdutide, efinopegdutide, efinopegdutide, Placebo to MK-6024, efinopegdutide
MK-6024-017
Phase 2 small_molecule active
Quick answer
efinopegdutide, efinopegdutide, efinopegdutide, Placebo to MK-6024, efinopegdutide for Metabolic Dysfunction-Associated Steatohepatitis is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Metabolic Dysfunction-Associated Steatohepatitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active